USPTO serial 87891744
LEUKOLIFE
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- LORENZO, KATHLEEN H
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with LEUKOLIFE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Aaron D. Hendelman
Aaron D. Hendelman WILSON SONSINI GOODRICH & ROSATI650 PAGE MILL ROADPALO ALTO, CA 94304-1050UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Assays and reagents for research purposes; diagnostic preparations for scientific use; diagnostic reagents for scientific research relating to molecular identification and digital quantification; diagnostic test kits for scientific use comprising reagents, slides, solid matrix materials, microfluidic devices and support documentation therefor; diagnostic test kits comprising reagents for scientific research relating to molecular identification and digital quantification; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; diagnostic reagents for clinical or medical laboratory use, namely, reagents for proteomics, RNA transcription and microRNA expression profiling, small-molecule analysis, single nucleotide polymorphisms analysis, DNA sequencing, detection of polymorphisms in human fluids, detection of copy number variations, and clinical, oncology, and hematology diagnostics; reagents for scientific or medical research use, diagnostic preparations and reagents for scientific or research uses, namely, RNA transcription profiling, proteomics, clinical diagnostics of samples containing microorganisms or human fluids, small-molecule analysis, single nucleotide polymorphisms analysis, and DNA sequencing; test kits, consisting of chemical preparations for scientific purposes, in particular for the detection, diagnosis, progress monitoring and progress prediction of diseases, including inflammations, infections, disorders of the central nervous systems, cardiovascular, neurological, endocrine, autoimmune and genetic disorders and cancers; assays, reagents, enzymes, polymerases, buffers and nucleotides, and kits comprised thereof, all for scientific or research use; diagnostic reagents for scientific in vitro use in biochemistry, clinical chemistry and microbiology, RNA and microRNA expression transcription profiling, proteomics, clinical diagnostics, small-molecule analysis, single nucleotide polymorphisms analysis, and DNA sequencing | ACTIVE | — |
| 005 | Gene therapy products, namely, living and genetically engineered tissues for use in predictive and diagnostic medical purposes; medical diagnostic reagents; medical diagnostic reagents and assays for testing and predicting patient recovery; medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection; diagnostic test kits for medical use comprising reagents, slides, solid matrix materials, microfluidic devices sold as a unit with instructional manuals therefor; medical diagnostic test kits for detecting pathogens, comprising reagents for medical use; medical diagnostic reagents for RNA transcription and microRNA expression profiling, proteomics, small molecule analysis, single nucleotide polymorphisms analysis, DNA sequencing, detection of polymorphisms in human fluids, detection of copy number variations, and clinical, oncology, and hematology diagnostics; medical diagnostic reagents and diagnostic reagents for clinical or medical laboratory use, diagnostic reagents for medical in vitro use in biochemistry, clinical chemistry and microbiology, RNA and microRNA expression transcription profiling, proteomics, clinical diagnostics, small-molecule analysis, single nucleotide polymorphisms analysis, and DNA sequencing; tests designed to isolate and extract cells for genetic analysis comprised of reagents for medical diagnostic use; medical diagnostic reagents and assays for testing of body fluids; kits consisting primarily of medical diagnostic reagents and assays for testing of body fluids; reagents in the form of cell markers and molecule markers for medical purposes | ACTIVE | — |
| 042 | Custom design and development of chemical reagents and biochemical assays; research and product development services for others in the field of biotechnology; providing laboratory research services in the field of gene expression; genetic data mining; providing molecule identification methods for acquiring, analyzing and managing biological and genetic information, in the fields of genetics and environment; research and development services for others in the field of diagnostic compounds for use in medicine, measuring apparatus for use in product research and development, separation and purification processes, environmental and testing processes, and industrial quality control processes; developing systems for acquiring, analyzing, and managing biological and genetic information in the fields of diagnostic reagents, forensics, medicine, genetics, and environment; research, design, and development services for others in the fields of diagnostic reagents, compounds and devices, measuring apparatus for use in product research and development, separation and purification processes, environmental and testing processes and industrial quality control processes; chemical screening analysis for others | ACTIVE | — |
| 044 | Medical diagnostic testing, monitoring and reporting services; genetic medical testing service; providing medical information to patients and medical professionals in the form of reports in a wide variety of medical fields; medical services; providing information relating to diagnostic, prophylactic and therapeutic properties of assays and reagents; providing medical record analysis services designed to provide patients and medical professionals with custom tailored information about the range of possible diagnoses and therapies | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by LeukoLifeDx, Inc.
- Other trademarks owned by LeukoLifeDx, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named LEUKOLIFE
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 10, 2022 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jan 10, 2022 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jun 4, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 2, 2021 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Jun 2, 2021 | EXT4 | SOU EXTENSION 4 FILED | — |
| Jun 2, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 26, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 24, 2020 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Nov 24, 2020 | EXT3 | SOU EXTENSION 3 FILED | — |
| Nov 24, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 5, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 3, 2020 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jun 3, 2020 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jun 3, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 19, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 15, 2019 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Nov 15, 2019 | EXT1 | SOU EXTENSION 1 FILED | — |
| Nov 15, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 4, 2019 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Apr 9, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 9, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 20, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 1, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 1, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 1, 2019 | ALIE | ASSIGNED TO LIE | — |
| Feb 27, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 27, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 27, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 27, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 27, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 26, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 27, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 27, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 27, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 14, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| May 3, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 27, 2018 | NWAP | NEW APPLICATION ENTERED | — |